D-1001-2020 Class III Terminated

Recalled by The Harvard Drug Group — Livonia, MI

FDA drug recall D-1001-2020 was initiated by The Harvard Drug Group on Feb 27, 2020 and is designated Class III. Reason for recall: Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets. The recall status is terminated (terminated Sep 24, 2022). Affected quantity: 115 cartons.

Recall details

Product Type
Drugs
Report Date
Mar 18, 2020
Initiation Date
Feb 27, 2020
Termination Date
Sep 24, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
115 cartons

Product description

Quetiapine Fumarate Extended-Release Tablets, 200 mg, 100 tablets per unit dose carton, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.) 454775 India; Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA. NDC: 0904-6803-61

Reason for recall

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Distribution pattern

Nationwide

Code information

Lot, expiry: Lot N00037, exp 05/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1001-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1001-2020. Report a data issue: hello@regdatalab.com.